Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Breast cancer
OMD
Oligometastases
Radiotherapy
Stereotactic body radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
08
03
2022
accepted:
24
03
2022
pubmed:
9
5
2022
medline:
25
6
2022
entrez:
8
5
2022
Statut:
ppublish
Résumé
Evidence from a few small randomized trials and retrospective cohorts mostly including various tumor entities indicates a prolongation of disease free survival (DFS) and overall survival (OS) from local ablative therapies in oligometastatic disease (OMD). However, it is still unclear which patients benefit most from this approach. We give an overview of the several aspects of stereotactic body radiotherapy (SBRT) in extracranial OMD in breast cancer from a radiation oncology perspective. A PubMed search referring to this was conducted. An attempt was made to relate the therapeutic efficacy of SBRT to various prognostic factors. Data from approximately 500 breast cancer patients treated with SBRT for OMD in mostly in small cohort studies have been published, consistently indicating high local tumor control rates and favorable progression-free (PFS) and overall survival (OS). Predictors for a good prognosis after SBRT are favorable biological subtype (hormone receptor positive, HER2 negative), solitary metastasis, bone-only metastasis, and long metastasis-free interval. However, definitive proof that SBRT in OMD breast cancer prolongs DFS or OS is lacking, since, with the exception of one small randomized trial (n = 22 in the SBRT arm), none of the cohort studies had an adequate control group. Further studies are needed to prove the benefit of SBRT in OMD breast cancer and to define adequate selection criteria. Currently, the use of local ablative SBRT should always be discussed in a multidisciplinary tumor board.
Identifiants
pubmed: 35527272
doi: 10.1007/s00066-022-01938-x
pii: 10.1007/s00066-022-01938-x
pmc: PMC9217902
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-611Informations de copyright
© 2022. The Author(s).
Références
Rubin P (1968) Comment: are metastases curable? JAMA 204(7):612–613
doi: 10.1001/jama.1968.03140200052016
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12):1208–1215. https://doi.org/10.1016/S1470-2045(13)70447-9
doi: 10.1016/S1470-2045(13)70447-9
pubmed: 24120480
Pastorino U, Buyse M, Friedel G et al (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113(1):37–49. https://doi.org/10.1016/s0022-5223(97)70397-0
doi: 10.1016/s0022-5223(97)70397-0
pubmed: 9011700
Robertson DJ, Stukel TA, Gottlieb DJ et al (2009) Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 115(4):752–759. https://doi.org/10.1002/cncr.24081
doi: 10.1002/cncr.24081
pubmed: 19130462
Treasure T, Fiorentino F, Scarci M et al (2012) Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames cancer registry data. BMJ Open. https://doi.org/10.1136/bmjopen-2012-001736
doi: 10.1136/bmjopen-2012-001736
pubmed: 23048062
pmcid: 3488730
Wei AC, Greig PD, Grant D et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13(5):668–676. https://doi.org/10.1245/ASO.2006.05.039
doi: 10.1245/ASO.2006.05.039
pubmed: 16523369
Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14(1):e28–37. https://doi.org/10.1016/S1470-2045(12)70510-7
doi: 10.1016/S1470-2045(12)70510-7
pubmed: 23276369
Milano MT, Biswas T, Simone CB 2nd et al (2021) Oligometastases: history of a hypothesis. Ann Palliat Med 10(5):5923–5930. https://doi.org/10.21037/apm.2020.03.31
doi: 10.21037/apm.2020.03.31
pubmed: 32279519
Milano MT, Katz AW, Zhang H et al (2019) Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol 131:45–51. https://doi.org/10.1016/j.radonc.2018.11.022
doi: 10.1016/j.radonc.2018.11.022
pubmed: 30773186
Makhlin I, Fox K (2020) Oligometastatic breast cancer: is this a curable entity? A contemporary review of the literature. Curr Oncol Rep 22(2):15. https://doi.org/10.1007/s11912-020-0867-2
doi: 10.1007/s11912-020-0867-2
pubmed: 32025905
pmcid: 7219961
Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1
doi: 10.1016/S1470-2045(19)30718-1
pubmed: 31908301
Willmann J, Badra EV, Adilovic S et al (2022) Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. https://doi.org/10.1016/j.radonc.2022.01.019
doi: 10.1016/j.radonc.2022.01.019
pubmed: 35688398
Pitroda SP, Weichselbaum RR (2019) Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol 16(9):581–588. https://doi.org/10.1038/s41571-019-0220-6
doi: 10.1038/s41571-019-0220-6
pubmed: 31092903
Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol 148:157–166. https://doi.org/10.1016/j.radonc.2020.04.003
doi: 10.1016/j.radonc.2020.04.003
pubmed: 32388150
Tsai CJ, Yang JT, Guttmann DM et al (2021) Consolidative use of radiotherapy to block (CURB) oligoprogression—interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int J Radiat Oncol Biol Phys 111(5):2. https://doi.org/10.1016/j.ijrobp.2021.09.014
doi: 10.1016/j.ijrobp.2021.09.014
David S, Tan J, Savas P et al (2020) Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast 49:55–62. https://doi.org/10.1016/j.breast.2019.10.016
doi: 10.1016/j.breast.2019.10.016
pubmed: 31734589
Scorsetti M, Franceschini D, De Rose F et al (2016) Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast 26:11–17. https://doi.org/10.1016/j.breast.2015.12.002
doi: 10.1016/j.breast.2015.12.002
pubmed: 27017237
Lemoine P, Bruand M, Kammerer E et al (2021) Stereotactic body radiation therapy for oligometastatic breast cancer: a retrospective multicenter study. Front Oncol 11:736690. https://doi.org/10.3389/fonc.2021.736690
doi: 10.3389/fonc.2021.736690
pubmed: 34778049
pmcid: 8581293
Trovo M, Furlan C, Polesel J et al (2018) Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol 126(1):177–180. https://doi.org/10.1016/j.radonc.2017.08.032
doi: 10.1016/j.radonc.2017.08.032
pubmed: 28943046
Weykamp F, Konig L, Seidensaal K et al (2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol 10:987. https://doi.org/10.3389/fonc.2020.00987
doi: 10.3389/fonc.2020.00987
pubmed: 32676455
pmcid: 7333735
Tan H, Cheung P, Louie AV et al (2021) Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol 161:159–165. https://doi.org/10.1016/j.radonc.2021.06.012
doi: 10.1016/j.radonc.2021.06.012
pubmed: 34119585
Viani GA, Gouveia AG, Louie AV et al (2021) Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis. Radiother Oncol 164:245–250. https://doi.org/10.1016/j.radonc.2021.09.031
doi: 10.1016/j.radonc.2021.09.031
pubmed: 34624408
Chalkidou A, Macmillan T, Grzeda MT et al (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4
doi: 10.1016/S1470-2045(20)30537-4
pubmed: 33387498
Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37(18):1558–1565. https://doi.org/10.1200/JCO.19.00201
doi: 10.1200/JCO.19.00201
pubmed: 31067138
pmcid: 6599408
Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501
doi: 10.1001/jamaoncol.2017.3501
pubmed: 28973074
Milano MT, Katz AW, Zhang H et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878–886. https://doi.org/10.1016/j.ijrobp.2011.08.036
doi: 10.1016/j.ijrobp.2011.08.036
pubmed: 22172903
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5
doi: 10.1016/S0140-6736(18)32487-5
pubmed: 30982687
Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818
doi: 10.1200/JCO.20.00818
pubmed: 32484754
pmcid: 7460150
Dawood S, Broglio K, Ensor J et al (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21(11):2169–2174. https://doi.org/10.1093/annonc/mdq220
doi: 10.1093/annonc/mdq220
pubmed: 20427349
pmcid: 2962259
Wijetunga NA, Dos Anjos CH, Zhi WI et al (2021) Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. Cancer Med 10(15):5163–5174. https://doi.org/10.1002/cam4.4068
doi: 10.1002/cam4.4068
pubmed: 34159748
pmcid: 8335830
Onal C, Guler OC, Yildirim BA (2018) Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast 42:150–156. https://doi.org/10.1016/j.breast.2018.09.006
doi: 10.1016/j.breast.2018.09.006
pubmed: 30296648
Steenbruggen TG, Schaapveld M, Horlings HM et al (2021) Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer. JNCI Cancer Spectr 5(3):pkab10. https://doi.org/10.1093/jncics/pkab010
doi: 10.1093/jncics/pkab010
pmcid: 8099998
Patel PH, Palma D, McDonald F et al (2019) The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol) 31(12):824–833. https://doi.org/10.1016/j.clon.2019.05.015
doi: 10.1016/j.clon.2019.05.015
Guth U, Magaton I, Huang DJ et al (2014) Primary and secondary distant metastatic breast cancer: two sides of the same coin. Breast 23(1):26–32. https://doi.org/10.1016/j.breast.2013.10.007
doi: 10.1016/j.breast.2013.10.007
pubmed: 24215983
Holleczek B, Stegmaier C, Radosa JC et al (2019) Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis—results from a registry-based study from Germany. BMC Cancer 19(1):520. https://doi.org/10.1186/s12885-019-5710-5
doi: 10.1186/s12885-019-5710-5
pubmed: 31146706
pmcid: 6543576
Kucharczyk MJ, Parpia S, Walker-Dilks C et al (2017) Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat 164(1):13–25. https://doi.org/10.1007/s10549-017-4228-2
doi: 10.1007/s10549-017-4228-2
pubmed: 28401364
Kroeze SG, Fritz C, Hoyer M et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37. https://doi.org/10.1016/j.ctrv.2016.11.013
doi: 10.1016/j.ctrv.2016.11.013
pubmed: 28056412
Bosacki C, Bouleftour W, Sotton S et al (2021) CDK 4/6 inhibitors combined with radiotherapy: a review of literature. Clin Transl Radiat Oncol 26:79–85. https://doi.org/10.1016/j.ctro.2020.11.010
doi: 10.1016/j.ctro.2020.11.010
pubmed: 33319074
Ho AY, Wright JL, Blitzblau RC et al (2020) Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists. Int J Radiat Oncol Biol Phys 108(1):227–241. https://doi.org/10.1016/j.ijrobp.2020.05.011
doi: 10.1016/j.ijrobp.2020.05.011
pubmed: 32417409
pmcid: 7646202
Anscher MS, Arora S, Weinstock C et al (2022) Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.6439
doi: 10.1001/jamaoncol.2021.6439
pubmed: 34989781
Kroeze SGC, Fritz C, Basler L et al (2019) Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. Strahlenther Onkol 195(3):199–206. https://doi.org/10.1007/s00066-018-01422-5
doi: 10.1007/s00066-018-01422-5
pubmed: 30737541
Kroeze SGC, Fritz C, Schaule J et al (2021) Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis. Cancers (Basel). https://doi.org/10.3390/cancers13194780
doi: 10.3390/cancers13194780
Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20(9):2828–2834. https://doi.org/10.1245/s10434-013-2998-2
doi: 10.1245/s10434-013-2998-2
pubmed: 23653043
Lane WO, Thomas SM, Blitzblau RC et al (2019) Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. Ann Surg 269(3):537–544. https://doi.org/10.1097/SLA.0000000000002621
doi: 10.1097/SLA.0000000000002621
pubmed: 29227346
Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16(13):1380–1388. https://doi.org/10.1016/S1470-2045(15)00135-7
doi: 10.1016/S1470-2045(15)00135-7
pubmed: 26363985
Khan SA, Zhao F, Solin LJ, Goldstein LJ (2020) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in woman with de-novo stage IV breast cancer: a trial of the ECOg-ACRIN research group (E2108). J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA2
doi: 10.1200/JCO.2020.38.18_suppl.LBA2
pubmed: 33373276
pmcid: 8078252
Krug D, Vonthein R, Illen A et al (2021) Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer: study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol 28:90–96. https://doi.org/10.1016/j.ctro.2021.03.012
doi: 10.1016/j.ctro.2021.03.012
pubmed: 33912695
pmcid: 8065185
Alomran R, White M, Bruce M et al (2021) Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer 21(1):303. https://doi.org/10.1186/s12885-021-08042-w
doi: 10.1186/s12885-021-08042-w
pubmed: 33757458
pmcid: 7989018
Schmitt D, Blanck O, Gauer T et al (2020) Technological quality requirements for stereotactic radiotherapy : expert review group consensus from the DGMP working group for physics and technology in stereotactic radiotherapy. Strahlenther Onkol 196(5):421–443. https://doi.org/10.1007/s00066-020-01583-2
doi: 10.1007/s00066-020-01583-2
pubmed: 32211939
pmcid: 7182540
Guckenberger M, Baus WW, Blanck O et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 196(5):417–420. https://doi.org/10.1007/s00066-020-01603-1
doi: 10.1007/s00066-020-01603-1
pubmed: 32211940
pmcid: 7182610
Gerhard SG, Palma DA, Arifin AJ et al (2021) Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol 11(4):e355–e365. https://doi.org/10.1016/j.prro.2021.03.005
doi: 10.1016/j.prro.2021.03.005
pubmed: 34217495
Timmerman R (2022) A story of hypofractionation and the table on the wall. Int J Radiat Oncol Biol Phys 112(1):4–21. https://doi.org/10.1016/j.ijrobp.2021.09.027
doi: 10.1016/j.ijrobp.2021.09.027
pubmed: 34919882
Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol) 30(1):5–14. https://doi.org/10.1016/j.clon.2017.09.007
doi: 10.1016/j.clon.2017.09.007
Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):4078–4101. https://doi.org/10.1118/1.3438081
doi: 10.1118/1.3438081
pubmed: 20879569